Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib

Marc Loriaux, Michael Deininger

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Treatment of chronic myeloid leukemia (CML) with imatinib (Gleevec®) induces a much higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN)-based therapies. Conventional wisdom suggests that elimination of the Philadelphia (Ph)- positive cells will lead to re-establishment of normal Ph-negative hematopoiesis. Surprisingly, karyotypic abnormalities were detected in the chromosome negative cells of some patients with cytogenetic response to imatinib. In some cases, this was associated with a myelodysplastic syndrome (MDS). While clonal evolution in Ph-positive cells is considered part of the progression of CML, clonal evolution in Ph-negative cells had been observed only rarely in a small number of patients treated with IFN or bone marrow transplantation, raising the question whether the phenomenon may be causally linked to imatinib therapy. In this manuscript, we will review the currently available data, suggest possible causes and discuss potential implications for patient management. We are fully aware that a systematic study of a larger patient cohort will be required to conclusively address these issues.

Original languageEnglish (US)
Pages (from-to)2197-2203
Number of pages7
JournalLeukemia and Lymphoma
Volume45
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosome Aberrations
Clonal Evolution
Cytogenetics
Interferons
Myelodysplastic Syndromes
Hematopoiesis
Bone Marrow Transplantation
Therapeutics
Chromosomes
Imatinib Mesylate

Keywords

  • Chronic myelogenous leukemia
  • Clonal evolution
  • Imatinib mesylate
  • Philadelphia-negative hematopoiesis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. / Loriaux, Marc; Deininger, Michael.

In: Leukemia and Lymphoma, Vol. 45, No. 11, 11.2004, p. 2197-2203.

Research output: Contribution to journalArticle

@article{68ec3c23ba5f4516bc6e1bf2c15e1e80,
title = "Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib",
abstract = "Treatment of chronic myeloid leukemia (CML) with imatinib (Gleevec{\circledR}) induces a much higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN)-based therapies. Conventional wisdom suggests that elimination of the Philadelphia (Ph)- positive cells will lead to re-establishment of normal Ph-negative hematopoiesis. Surprisingly, karyotypic abnormalities were detected in the chromosome negative cells of some patients with cytogenetic response to imatinib. In some cases, this was associated with a myelodysplastic syndrome (MDS). While clonal evolution in Ph-positive cells is considered part of the progression of CML, clonal evolution in Ph-negative cells had been observed only rarely in a small number of patients treated with IFN or bone marrow transplantation, raising the question whether the phenomenon may be causally linked to imatinib therapy. In this manuscript, we will review the currently available data, suggest possible causes and discuss potential implications for patient management. We are fully aware that a systematic study of a larger patient cohort will be required to conclusively address these issues.",
keywords = "Chronic myelogenous leukemia, Clonal evolution, Imatinib mesylate, Philadelphia-negative hematopoiesis",
author = "Marc Loriaux and Michael Deininger",
year = "2004",
month = "11",
doi = "10.1080/10428190410001723278",
language = "English (US)",
volume = "45",
pages = "2197--2203",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib

AU - Loriaux, Marc

AU - Deininger, Michael

PY - 2004/11

Y1 - 2004/11

N2 - Treatment of chronic myeloid leukemia (CML) with imatinib (Gleevec®) induces a much higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN)-based therapies. Conventional wisdom suggests that elimination of the Philadelphia (Ph)- positive cells will lead to re-establishment of normal Ph-negative hematopoiesis. Surprisingly, karyotypic abnormalities were detected in the chromosome negative cells of some patients with cytogenetic response to imatinib. In some cases, this was associated with a myelodysplastic syndrome (MDS). While clonal evolution in Ph-positive cells is considered part of the progression of CML, clonal evolution in Ph-negative cells had been observed only rarely in a small number of patients treated with IFN or bone marrow transplantation, raising the question whether the phenomenon may be causally linked to imatinib therapy. In this manuscript, we will review the currently available data, suggest possible causes and discuss potential implications for patient management. We are fully aware that a systematic study of a larger patient cohort will be required to conclusively address these issues.

AB - Treatment of chronic myeloid leukemia (CML) with imatinib (Gleevec®) induces a much higher rate of partial and complete cytogenetic responses (CCR) than interferon-α (IFN)-based therapies. Conventional wisdom suggests that elimination of the Philadelphia (Ph)- positive cells will lead to re-establishment of normal Ph-negative hematopoiesis. Surprisingly, karyotypic abnormalities were detected in the chromosome negative cells of some patients with cytogenetic response to imatinib. In some cases, this was associated with a myelodysplastic syndrome (MDS). While clonal evolution in Ph-positive cells is considered part of the progression of CML, clonal evolution in Ph-negative cells had been observed only rarely in a small number of patients treated with IFN or bone marrow transplantation, raising the question whether the phenomenon may be causally linked to imatinib therapy. In this manuscript, we will review the currently available data, suggest possible causes and discuss potential implications for patient management. We are fully aware that a systematic study of a larger patient cohort will be required to conclusively address these issues.

KW - Chronic myelogenous leukemia

KW - Clonal evolution

KW - Imatinib mesylate

KW - Philadelphia-negative hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=8644286697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644286697&partnerID=8YFLogxK

U2 - 10.1080/10428190410001723278

DO - 10.1080/10428190410001723278

M3 - Article

C2 - 15512807

AN - SCOPUS:8644286697

VL - 45

SP - 2197

EP - 2203

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -